China And US Added to Amneal-Iconovo Symbicort Alliance
Expands Agreement Disclosed In May Last Year
Swedish player Iconovo is in line for larger future royalties through its partnership with Amneal covering a generic version of AstraZeneca’s Symbicort, after the two firms signed a new, expanded agreement.
You may also be interested in...
Viatris may be able to move earlier than anticipated with its Breyna proposed generic version of Symbicort, after the US Court of Appeals for the Federal Circuit found that a lower court had misinterpreted claims of Symbicort patents for which Viatris has stipulated to infringement.
Viatris and partner Kindeva Drug Delivery are celebrating a first tentative nod for a generic to one of the most significant respiratory opportunities in the US, but cannot launch at present with the firms having failed to navigate key pieces of intellectual property.
With its own interests in the branded eye-disease space, Regeneron has commented on ranibizumab biosimilar sponsor Biogen’s fortunes during a recent conference.